van Nassau, Sietske C. M. W.
Bol, Guus M.
van der Baan, Frederieke H.
Roodhart, Jeanine M. L.
Vink, Geraldine R.
Punt, Cornelis J. A.
May, Anne M.
Koopman, Miriam
Derksen, Jeroen W. G.
Article History
Accepted: 17 January 2024
First Online: 17 February 2024
Compliance with Ethical Standards
:
: S.N. reports receiving support for travel from Servier via institution outside the submitted work. G.B. reports a patent for biomarker DDX3, receiving institutional grants from Bayer, Terumo and Servier, and honoraria for lectures from Pierre Fabre, Terumo and Bayer outside the submitted work. F.B. reports receiving an institutional grant from Personal Genome Diagnostics (PGDx) outside the submitted work. J.R. reports receiving institutional grants from Bristol Myers Squibb, Pierre Fabre, Servier, HUB 4 organoids, Clear Biotech, GSK, Cilis biotech, DoMore diagnostics, receiving consulting fees via institution from Bayer, Bristol Myers Squibb, Merck-Serono, Pierre Fabre, Servier, GSK, Amgen, has received payment via institution for lectures from Bristol Myers Squibb, Pierre Fabre and Servier, support for meetings and/or travel from Servier, participates on a Data Safety Monitoring Board or Advisory Board for PELVEX and MENDIT, and non-remunerated activity in the ONCODE clinical advisory board, KWF scientific board, and Hubrecht Organoid Biobank foundation management board, all outside the submitted work. G.V. reports receiving institutional grants from PGDx, Delfi diagnostics, Merck, Servier, Bayer, Bristol Myers Squibb, Sirtex and Pierre Fabre outside the submitted work. C.P. reports receiving consulting fees via institution from Nordic Pharma, outside the submitted work.M.K. reports institutional scientific grants from Bayer, Bristol Myers Squibb, Merck, PGDx, Pierre Fabre, Roche, Sirtex and Servier, has an advisory role for Eisai, Nordic Farma, Merck-Serono, Pierre Fabre, and Servier, is principal investigator of the Prospective Dutch CRC (PLCRC) cohort and the international cohort study PROMETCO with Servier as sponsor, and reports non-remunerated activity as vice-chair for the Dutch Colorectal Cancer Group, chair of the ESMO Real World Data and Digital Health Working Group, and involvement in several colorectal cancer clinical trials as PI or co-investigator, all outside the submitted work. A.M. and J.D. declare no conflict of interest.
: This article does not contain any experiments with human or animal subjects performed by any of the authors.